

AFA-Nanocrystal[™] Production

Batch-scale (2mL) Indomethacin Preparation Protocol

This page intentionally left blank

INTENDED USE

This protocol is for the preparation of indomethacin API nanocrystals on a 2mL (11.4mg) scale.

SUMMARY OF OPERATING CONDITIONS

AFA Instrument	S220x
Peak Incident Power	150 W
Duty Factor	50%
Cycles per Burst	1000
Duration	1200 seconds
Bath Temperature	10°C
Power Mode	Frequency sweeping
Degassing mode	Continuous
Volume	2mL (12x24 vessel)

Table 1: Operating Conditions

Recommended settings are subject to change without notice.

See <http://covarisinc.com/resources/protocols/> for updates to this document.

SUPPLIES

Item	Description	Part Number
Focused-Ultrasonicator™	S220x with Computer and Software	S220x
Sample Vessel	Tube and Cap 12x24mm	520056
Sample Holder	Holder 12x24 Tube	500199
Sample drug	Indomethacin	MP Biomedicals LLC 02190217
Solvent	N,N-dimethylacetamide (DMA)	ARK2190 – Sigma-Aldrich
Stabilizer	PVP30 (polyvinylpyrrolidone) Sodium Lauryl Sulfate (SLS)	Kollidon BASF Sigma-Aldrich

Table 2: Supplies

ADDITIONAL MATERIALS (SUPPLIED BY USER):

- Particle sizer and software (E.g. Malvern Mastersizer3000)
- Variable pipette and tips: 200 µL and 1000 µL
- Disposable cuvettes, 1mL

Values mentioned in this Quick Guide are nominal values. The tolerances are as follows:

- Temperature +/-2°C

RISK AND SAFETY INFORMATION

The following protocol uses compounds and organic solvents that according to the Globally Harmonized System of Classification and Labeling of Chemicals (GHS) is considered hazardous. In the manufacturer's experience, they have no harmful effects when used and handled according to instructions. The MSDS for the chemicals are available from the suppliers.

OPERATING CONDITIONS

1. Fill the tank with fresh deionized water to the fill line marked 15. The S220x should be equipped with a graduated water level label. If the tank lacks this label, please contact Covaris. During treatments, the tube should be partially immersed in the water to ensure a good acoustic path from the AFA transducer.
2. Degas water for the recommended 30 minutes or more. To maintain degassed water, keep the pump continuously on during operation and sample processing. Do not turn the pump off.
3. Set the chiller to the proper temperature, as listed for "Bath Temperature" in Table 1.

RECOMMENDATIONS SPECIFIC FOR NANOSUSPENSION FORMATION

The Covaris AFA process is highly reproducible, however steps should be taken to ensure the best results. The bath water is employed to couple acoustic energy to the sample vessel, thus attention must be paid to the following water treatment attributes to obtain the best results:

1. Purity: When applying acoustics in rate-limited applications, foreign materials such as algae and particulates may scatter the high frequency focused acoustic beam. Bath water should be pure distilled or DI water, changed daily or cleansed by a Covaris Water Conditioning System.
2. Degas Level: Similarly, insufficient degas levels within the bath may result in poor acoustic coupling. System degas pumps should be run in advance of and during AFA treatments, as detailed in instrument User Manuals.
3. Temperature: Warmer temperatures promote less forceful collapse of acoustic cavities within the sample fluid. Bath temperature (as reported by SonoLAB software) should therefore be closely controlled and matched run-to-run and day-to-day. Employ the temperature alert feature in SonoLAB to warn of a failure to maintain control of bath temperature.
4. Level: Attention should be paid to maintaining a consistent water level, according to published protocols. If using a Covaris Water Conditioning System, check levels daily to restore water lost to evaporation.

In summary, when employing the Covaris AFA, control and verification of treatment attributes and water quality will reduce variance and promote consistent, satisfactory results.

PROTOCOL

1. Prepare a 125mM stock solution of indomethacin. To make 5mL of the stock, dissolve 223.6mg of indomethacin in 5mL of dimethylacetamide.
2. Prepare a 0.2%PVP30, 0.25mM SLS antisolvent stock solution. To make 100mL of the stock, dissolve 240mg of PVP30 (Kollidon30) and 7.21mg of SLS in 100mL of deionized water.

3. Set up the Covaris S220x at the appropriate temperature following the operating conditions above.
4. Add 1700 μL of the vehicle (0.2%PVP30 and 0.25mMSLS) to the sample vessel.
5. Add 256 μL of a 125 mM stock solution of indomethacin in dimethylacetamide to the sample vessel and cap the tube. This will result in a 6.6:1 ratio of the vehicle to the drug solution (i.e. the drug concentration will be 16.4mM). Be careful not to introduce bubbles into the tube, which may happen due to incorrect pipetting. CAUTION: The bottom of the tube is in the acoustic field. Therefore, a bubble in the sample will deflect energy and induce variable results.
6. Quickly but carefully load the sample vessel into the appropriate holder, and insert the holder into the S220x instrument.
7. Initiate and Run process according to the operating conditions specified in Table 1.
8. Particle size measurements are taken immediately and 24 hours after the particles were prepared (to allow for time for equilibration to a stable particle size).

Note: Once the solvent and antisolvent have been combined, crystallization will start immediately. Without AFA treatment, crystals will grow in an uncontrolled manner. As such, load the sample and start the AFA promptly after combining the solvent and antisolvent.

DETERMINATION OF PARTICLE SIZE

A Malvern Zetasizer ZS-90 may be used to analyze the nanosuspension. The method is as follows.

1. Set up the Malvern Zetasizer according to its setup instructions.
2. Add 1mL of the processed sample to the cuvette.
3. Ensure that the sample is homogeneous and that there are no air bubbles in the cuvette.
4. Place in Zetasizer instrument and run analysis.

Typical output readings

	Z-average [d.nm]	PDI
1	219	0.174
2	198	0.166
3	222	0.168
Average	213	0.169333
SD	13.07669683	0.004163
CV	0.061392943	0.024587

Table 3: Variation in results of replicates, taken 24 hours after the particles were prepared (to allow for time for equilibration to a stable particle size)




Figure 1: Variation of indomethacin Nanocrystal™ formation results, taken 24 hours after the particles were prepared (to allow for time for equilibration to a stable particle size)